Short Interest in Soligenix, Inc. (NASDAQ:SNGX) Expands By 183.0%

Soligenix, Inc. (NASDAQ:SNGX) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 39,900 shares, an increase of 183.0% from the May 31st total of 14,100 shares. Approximately 4.1% of the company’s shares are sold short. Based on an average daily volume of 198,600 shares, the days-to-cover ratio is presently 0.2 days.

Soligenix Stock Down 2.6 %

Soligenix stock traded down $0.07 during mid-day trading on Friday, hitting $2.58. 277,188 shares of the stock were exchanged, compared to its average volume of 145,661. The firm’s fifty day simple moving average is $5.30 and its two-hundred day simple moving average is $8.69. The stock has a market capitalization of $2.55 million, a price-to-earnings ratio of -0.22 and a beta of 1.93. Soligenix has a 12 month low of $2.50 and a 12 month high of $32.00.

Soligenix (NASDAQ:SNGX) last released its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($2.88) earnings per share for the quarter, beating the consensus estimate of ($3.20) by $0.32. The company had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.20 million. Soligenix had a negative net margin of 1,025.66% and a negative return on equity of 198.36%. As a group, analysts forecast that Soligenix will post -9.2 earnings per share for the current fiscal year.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.